Condition: CLL/SLL · Waldenstrom Macroglobulinemia · Follicular Lymphoma · Sponsor: Newave Pharmaceutical Inc
This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibitor.
This description comes directly from the study's public registry record.
Anna Chen, MD, PhD · (206) 335-3820 · yu@newavepharma.com
Stephen Anthony, DO · s.anthony@newavepharma.com
Always discuss trial participation with your own doctor first.
| Duke Univerisity | Durham, North Carolina, United States | Recruiting |
| University of Cincinnati | Cincinnati, Ohio, United States | Recruiting |
| Ohio State University | Columbus, Ohio, United States | Recruiting |
| Huntsman Cancer Institute, University of Utah | Salt Lake City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04775745